The Glucagon-Like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: A randomized controlled trial
However, some patients experience persistent symptoms that may limit medication tolerance or necessitate discontinuation
Among SUs, KDIGO prefers glipizide for patients under dialysis, since it is largely metabolized in the liver and poses a lower hypoglycemic risk compared to other SUs [69]
Research has investigated its effects on metabolic markers including HbA1c, fasting glucose, lipid profiles, and hepatic lipid content in preclinical and clinical models
Sie sehen gerade einen Platzhalterinhalt von YouTube
A study recently put this theory to the test